Global Recurrent Parotitis Treatment Market – Industry Trends and Forecast to 2030

Recurrent Parotitis Treatment Market Analysis and Size

The incidence of recurrent Parotitis in children, is more commonly reported, with an estimated incidence ranging from 0.2% to 5% in the pediatric population. It is more prevalent in males than females, and the condition often presents between the ages of 3 and 5 years. In adults, the incidence of recurrent Parotitis is lower compared to children but can still occur.

Data Bridge Market Research analyses that the recurrent global parotitis treatment market which was USD 5,169.56 million in 2022, is expected to reach USD 8,364.68 million by 2030, and is expected to undergo a CAGR of 6.2% during the forecast period 2023-2030. This indicates the market value. “Surgical Excision” dominates the treatment segment of the recurrent global parotitis treatment market owing to the growing demand for better surgical methods for treatment. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Recurrent Parotitis Treatment Market Scope and Segmentation

Market Definition

The swelling of one or both parotid glands, which are salivary glands positioned in the cheek between the ear and jaw on each side of the head, is known as parotitis. Recurrent parotitis is a recurrent parotid inflammation that is usually linked with non-obstructive parotid gland sialectasis. Recurrent parotitis in children is also termed as juvenile recurrent parotitis. Recurrent episodes of swelling and/or pain in the parotid gland, frequently accompanied by fever and malaise, characterize this condition. It generally affects youngsters, although it can also impact adults. It's a rare ailment, and the cause is yet unknown. Underproduction of saliva, a history of bacterial or viral infections, congenital deformity of the salivary ducts, genetic predisposition, or an underlying autoimmune condition are some of the possibilities being investigated by researchers. Swelling of the parotic glands appears to be caused by a disruption in the usual flow of saliva, which leads to infection of the parotid glands.

Global Recurrent Parotitis Treatment Market Dynamics

Drivers

• Increasing Prevalence of Recurrent Parotitis

The rising incidence of recurrent Parotitis among the population is a major driver for the growth of the treatment market. As more people are diagnosed with the condition, the demand for effective treatment options increases.

• Advancements in Medical Technology

Technological advancements in diagnostic techniques and treatment modalities have improved the accuracy of diagnosis and enhanced the effectiveness of treatment. This has led to increased adoption of treatment options for recurrent Parotitis.

• Rising Demand for Minimally Invasive Procedures

The preference for minimally invasive procedures, such as Sialendoscopy, in the treatment of recurrent Parotitis has increased. These procedures offer less pain, shorter recovery time, and reduced risk of complications, driving their adoption in the market

Opportunities

• Increasing Research and Development

Continued research and development efforts focused on understanding the underlying causes of recurrent Parotitis and developing more effective treatment options can create opportunities for innovative therapies. This includes the exploration of new drug formulations, targeted therapies, and personalized medicine approaches.

• Increasing Technological Advancements

Advancements in medical technology, such as improved imaging techniques and minimally invasive procedures, can enhance the accuracy of diagnosis and effectiveness of treatment. This can create opportunities for the adoption of advanced treatment modalities.

Restraints/Challenges

• High Cost of Treatment

Certain treatment options for recurrent Parotitis, such as Sialendoscopy and surgical interventions, can be expensive. The high cost of these procedures may limit their accessibility, especially in regions with limited healthcare resources or patients with financial constraint.

• Lack of Standardized Treatment Guidelines

There is a lack of standardized treatment guidelines for recurrent Parotitis, leading to variations in treatment approaches among healthcare providers. This can result in inconsistent treatment outcomes and hinder market growth.

• Potential Complications and Adverse Effects

Some treatment options for recurrent Parotitis, such as surgical interventions, carry the risk of complications and adverse effects. This can lead to patient concerns and reluctance to undergo certain treatments, impacting market growth.

• Challenges in Drug Development

Developing new drugs specifically targeting recurrent Parotitis can be challenging due to the complex nature of the condition. Limited research and development in this area may result in a lack of effective pharmacological treatment options.

This global recurrent parotitis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the recurrent global parotitis treatment market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.

Recent Developments

• In September 2021, Medtronic announced the launch of their new sialendoscopy product, the Medtronic SialoCath™ System, for the treatment of salivary gland disorders including recurrent parotitis. The system offers minimally invasive treatment options for patients
• In August 2021, Sonova Holding AG, a Swiss company specializing in hearing care solutions, announced a collaboration with the University of Zurich to develop a non-invasive treatment for recurrent parotitis using low-intensity focused ultrasound therapy
• In May 2021, Merck KGaA and Artios Pharma Limited announced a research collaboration to develop novel DNA damage response (DDR) targeted therapies for the treatment of various diseases, including recurrent parotitis. The collaboration aims to identify new treatment options based on DDR inhibitors
• In April 2021, Olympus Corporation, a global leader in medical technology, introduced their new EndoTherapy solutions for salivary gland disorders, including recurrent parotitis. The solutions include specialized devices for diagnosis and treatment

Global Recurrent Parotitis Treatment Market Scope

The global recurrent parotitis treatment market is segmented on the basis of treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Medications
• Antibiotics
• Analgesics
• Sialagogues
• Sialoendoscopy
• Parotidectomy
• Radiotherapy
• Tympanic Neurectomy
• Others
• Warm Compresses
• Others

 Diagnosis

• X-Ray
• Computed Tomography (CT) Scan
• Magnetic Resonance Imaging (MRI)
• Sialography
• Ultrasonography
• Others

Symptoms

• Fever
• Inflammation of the Parotid Gland
• Redness
• Recurrence of Inflammation and Swelling in Repeated Episodes
• Pain
• Others

Dosage

• Injection
• Tablets
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Clinic
• Hospital
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Recurrent Parotitis Treatment Market Regional Analysis/Insights

The global parotitis treatment market is analysed and market size insights and trends are provided by country, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel as referenced above.

The countries covered in the global recurrent parotitis treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the global recurrent parotitis treatment market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of people having recurrent parotitis.   

Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people and growing demand for advanced medical technology for treatment and diagnosis, the large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global recurrent parotitis treatment market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the global recurrent parotitis treatment market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the global recurrent parotitis treatment market. The data is available for the historic period 2015-2020

Competitive Landscape and Global Recurrent Parotitis Treatment Market Share Analysis

The global recurrent parotitis treatment market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the global recurrent parotitis treatment market.

Some of the major players operating in the global recurrent parotitis treatment market are:

• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Sanofi (France)
• Abbott (U.S.)
• Bayer AG (Germany)
• Bristol-Myers Squibb Company (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Johnson & Johnson Private Limited (U.S.)
• Mylan N.V. (U.S.)
• Allergan (Ireland)
• Merck & Co., Inc. (U.S.)
• Melinta Therapeutics LLC (U.S.)
• Basilea Pharmaceutica Ltd. (Switzerland)
• Tetraphase Pharmaceuticals (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India), SHIONOGI & Co., Ltd. (Japan)
• AbbVie Inc. (U.S.)
• Cumberland Pharmaceuticals Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• Boehringer Ingelheim International GmbH (Germany)
• Takeda Pharmaceutical Company Limited (Japan)

SKU-67515